Skip to main content

Talk Bio

Search This Blog

cAMPfield Raises $180M to Bring PDE4 Inhibition to IBD

on June 19, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

cAMPfield Therapeutics recently raised $180 million in a Series A financing round to advance its oral PDE4B-selective inhibitor, prifemilast, for the treatment of inflammatory bowel disease (IBD), specifically moderate-to-severe ulcerative colitis and Crohn's disease.

The funding will be used to support global Phase IIb and Phase II trials of prifemilast, which is designed to minimize PDE4D-related gastrointestinal side effects while maintaining anti-inflammatory activity through PDE4B inhibition.

Sources:

cAMPfield Launches $180M IBD Therapy Challenge

Clinical Phases

Targeting Phosphodiesterase 4 in Gastrointestinal and Liver ...

Jack Shuang Hou's Post

Kyle LaHucik's Post - LinkedIn

LOCAL BIOACTIVATION AND EFFICACY OF PALI-2108: A ...

cAMPfield Therapeutics | Redefining the Treatment of Inflammatory ...

cAMPfield $180M Series A Funding (2026) | Investors & Contacts ...

cAMPfield's $180M Bet: A Safer Pill for Inflammatory Bowel Disease

cAMPfield Therapeutics has raised a $180M Series A, the latest well ...

News - cAMPfield Therapeutics

cAMPfield lands $180M to build gut disease drug - BioPharma Dive

PDE4 Inhibition and Inflammatory Bowel Disease - PMC - NIH

PDE4 inhibition: a novel approach for the treatment of ...

Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases

cAMPfield Crohn 's disease Inflammatory Bowel Diseases methionine Phase II Phosphodiesterase Type 4 prifemilast Psychological inhibition Ulcerative Colitis

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC